| 18.67 -0.49 (-2.56%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 23.24  |
1-year : | 27.14 |
| Resists | First : | 19.89 |
Second : | 23.24 |
| Pivot price | 16.09 |
|||
| Supports | First : | 15.99 |
Second : | 13.58 |
| MAs | MA(5) : | 17.44 |
MA(20) : | 15.96 |
| MA(100) : | 14.23 |
MA(250) : | 10.26 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 84  |
D(3) : | 75.9 |
| RSI | RSI(14): 68 |
|||
| 52-week | High : | 20.2 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BDSX ] has closed below upper band by 1.1%. Bollinger Bands are 4.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.91 - 20.01 | 20.01 - 20.09 |
| Low: | 18.28 - 18.39 | 18.39 - 18.46 |
| Close: | 18.51 - 18.68 | 18.68 - 18.81 |
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Mon, 22 Jun 2026
Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fri, 19 Jun 2026
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains? - Yahoo Finance
Thu, 18 Jun 2026
BIODESIX INC (BDSX) Stock Chart - ChartMill
Thu, 18 Jun 2026
BDSX News | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Thu, 18 Jun 2026
Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX) - Stock Titan
Mon, 15 Jun 2026
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 41.9 (%) |
| Held by Institutions | 38.7 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 148 (K) |
| EPS | -3.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | -33.3 % |
| Operating Margin | -25.9 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -316.6 % |
| Qtrly Rev. Growth | 42.2 % |
| Gross Profit (p.s.) | 7.57 |
| Sales Per Share | 9.27 |
| EBITDA (p.s.) | -1.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -4.72 |
| PEG Ratio | 0 |
| Price to Book value | 20.74 |
| Price to Sales | 2.01 |
| Price to Cash Flow | -7.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|